Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Cash & Current Investments (2023 - 2025)

Historic Cash & Current Investments for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $2.6 million.

  • Zhengye Biotechnology Holding's Cash & Current Investments changed N/A to $2.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.6 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2024, which is 3268.82% down from last year.
  • According to the latest figures from Q2 2025, Zhengye Biotechnology Holding's Cash & Current Investments is $2.6 million.
  • In the past 5 years, Zhengye Biotechnology Holding's Cash & Current Investments ranged from a high of $3.8 million in Q4 2023 and a low of $2.6 million during Q2 2025
  • For the 3-year period, Zhengye Biotechnology Holding's Cash & Current Investments averaged around $3.0 million, with its median value being $2.6 million (2024).
  • Over the last 5 years, Zhengye Biotechnology Holding's Cash & Current Investments had its largest YoY gain of 3139.86% in 2024, and its largest YoY loss of 3139.86% in 2024.
  • Zhengye Biotechnology Holding's Cash & Current Investments (Quarter) stood at $3.8 million in 2023, then plummeted by 31.4% to $2.6 million in 2024, then dropped by 0.68% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q2 2025, $2.6 million for Q4 2024, and $3.8 million during Q4 2023.